NYLIM
ALNY icon

New York Life Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

New York Life Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
4,304
+526
+14% +$159K 0.01% 639
2026
Q1 		$1.25M Buy
3,778
+2,033
+117% +$692K 0.01% 626
2025
Q4 		$694K Buy
1,745
+116
+7% +$51.3K 0.01% 676
2025
Q3 		$743K Sell
1,629
-474
-23% -$193K 0.01% 713
2025
Q2 		$686K Sell
2,103
-111
-5% -$30.7K 0.01% 711
2025
Q1 		$598K Sell
2,214
-170
-7% -$43.7K 0.01% 753
2024
Q4 		$561K Buy
2,384
+153
+7% +$40.2K 0.01% 774
2024
Q3 		$614K Sell
2,231
-32
-1% -$8.33K 0.01% 794
2024
Q2 		$550K Buy
2,263
+45
+2% +$7.1K 0.01% 796
2024
Q1 		$331K Buy
2,218
+20
+0.9% +$3.34K ﹤0.01% 1297
2023
Q4 		$421K Sell
2,198
-28
-1% -$4.77K ﹤0.01% 958
2023
Q3 		$394K Sell
2,226
-187
-8% -$35.7K ﹤0.01% 888
2023
Q2 		$458K Sell
2,413
-90
-4% -$17.8K ﹤0.01% 791
2023
Q1 		$501K Buy
2,503
+90
+4% +$18.9K 0.01% 671
2022
Q4 		$573K Sell
2,413
-29
-1% -$6.19K 0.01% 806
2022
Q3 		$489K Sell
2,442
-283
-10% -$54K 0.01% 760
2022
Q2 		$397K Buy
+2,725
New +$387K ﹤0.01% 974

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

New York Life Investment Management's ALNY Position: Q2 2026 in Review

New York Life Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 14% in Q2 2026, buying an estimated $159K and bringing the position to 4,304 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #639.

New York Life Investment Management first reported a position in ALNY in Q2 2022 and has held it in 17 quarters since. 511 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • New York Life Investment Management held 4,304 shares of Alnylam Pharmaceuticals worth $1.3M as of Q2 2026.
  • New York Life Investment Management bought 526 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $159K.
  • Alnylam Pharmaceuticals made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #639 holding.
  • New York Life Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 511 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.